These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27505293)

  • 1. Anti-Viral Therapy and Decreased Sexual Desire in Patients with Chronic Hepatitis C.
    Hsiao PJ; Hsieh PF; Chou EC; Lai HC; Peng CY; Su KP
    PLoS One; 2016; 11(8):e0160450. PubMed ID: 27505293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN.
    Vabo IL; Ferreira LE; Pace FH
    Arq Gastroenterol; 2016; 53(1):20-4. PubMed ID: 27281500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.
    Rumi MG; Aghemo A; Prati GM; D'Ambrosio R; Donato MF; Soffredini R; Del Ninno E; Russo A; Colombo M
    Gastroenterology; 2010 Jan; 138(1):108-15. PubMed ID: 19766645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients.
    Ronzoni L; Aghemo A; Rumi MG; Prati G; Colancecco A; Porretti L; Monico S; Colombo M; Cappellini MD
    J Viral Hepat; 2014 Jun; 21(6):416-23. PubMed ID: 24750239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
    Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
    World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection.
    Di Bisceglie AM; Janczweska-Kazek E; Habersetzer F; Mazur W; Stanciu C; Carreno V; Tanasescu C; Flisiak R; Romero-Gomez M; Fich A; Bataille V; Toh ML; Hennequi M; Zerr P; Honnet G; Inchauspé G; Agathon D; Limacher JM; Wedemeyer H
    Gastroenterology; 2014 Jul; 147(1):119-131.e3. PubMed ID: 24657484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
    J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C.
    Comai S; Cavalletto L; Chemello L; Bernardinello E; Ragazzi E; Costa CV; Bertazzo A
    Pharmacol Res; 2011 Jan; 63(1):85-92. PubMed ID: 20940053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection.
    Mahajan S; Avasthi A; Grover S; Chawla YK
    J Psychosom Res; 2014 Aug; 77(2):109-15. PubMed ID: 25077851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.
    Hu CC; Lin CL; Kuo YL; Chien CH; Chen SW; Yen CL; Lin CY; Chien RN
    Aliment Pharmacol Ther; 2013 Jan; 37(1):81-90. PubMed ID: 23121150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
    Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1233-40. PubMed ID: 22098185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan.
    Lin JA; Chen YC; Cheng SN; Chen PJ; Chu HC; Hsieh TY; Shih YL
    J Formos Med Assoc; 2014 Oct; 113(10):727-33. PubMed ID: 24231092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated interferon and ribavirin-induced depression in chronic hepatitis C: role of personality.
    Castellvi P; Navinés R; Gutierrez F; Jiménez D; Márquez C; Subirà S; Solà R; Martín-Santos R
    J Clin Psychiatry; 2009 Jun; 70(6):817-28. PubMed ID: 19573480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
    Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients.
    Helal GK; Gad MA; Abd-Ellah MF; Mahgoup EM
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):553-7. PubMed ID: 26872109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
    PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of peginterferon-α2a plus ribavirin treatment in renal transplant recipients with chronic hepatitis C.
    Sanai FM; Mousa D; Al-Mdani A; Al-Shoail G; Al-Ashgar H; Al Meshari K; Al-Qahtani A; Saadeh M; Bzeizi KI; Aleid H
    J Hepatol; 2013 Jun; 58(6):1096-103. PubMed ID: 23428875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
    Tural C; Solà R; Alvarez NP; Moltó J; Sánchez M; Zamora AM; Ornelas A; Laguno M; González J; von Wichmann MÁ; Téllez MJ; Paredes R; Clotet B;
    Antivir Ther; 2011; 16(6):833-41. PubMed ID: 21900715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
    Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
    Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.